微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

壳交联pH响应型PLGA载药微球的制备与研究

首先采用一次乳化法制备出PLGA[聚(乳酸-羟基乙酸)]纳米微球,并通过静电吸附将阳离子聚合物壳聚糖修饰到PLGA微球表面,然后以香草醛为交联剂对壳聚糖进行化学交联,得到一种壳交联的p H响应型纳米微球(PCV),微球粒径为(277.60±38.01)nm,表面电位为(21.60±4.51)m V.微球稳定性评价结果显示微球在24 h内粒径变化较小;流式细胞仪检测显示细胞对PCV微球的摄取量比未经修饰的PLGA微球的摄取量高;空白微球细胞毒性实验表明在空白微球浓度小于80μg/m L时细胞的存活率达93.24%.以多西他赛(DTX)为模型药物进行包载,该纳米微球DTX的载药率为7.48%,包封率为34.98%;体外药物释放实验显示,该微球在p H=5.0环境下孵育90 h的药物积累释放率达58.66%,而在p H=7.4的环境下的药物积累释放率为50.63%;此外,载DTX微球毒性试验结果表明该载药微球对A549肺癌细胞有较强的杀伤作用,其IC50值可达0.0009μg/m L.     

5-氟尿嘧啶/壳聚糖载药纳米微球的制备及性能

以三聚磷酸钠为交联剂,采用离子交联法制备了5-氟尿嘧啶/壳聚糖纳米微球,评价其性能、体外释药性能及对人肺癌细胞GLC-82的体外杀伤效应,并通过Zeta电位和红外光谱分析载药纳米微球形成机理.结果表明,所制备的5-Fu/CS纳米微球平均包封率为32.3%,平均载药量为25.6%,平均粒径为253nm,平均zeta电势为+8.38mV,成球性及分散性良好.CS载药纳米微球具有缓释性能,体外释药行为符合双向动力学规律.在体外作用72h,CS载药纳米微球对人肺癌细胞GLC-82的杀伤率达66.6%,杀伤效果明显优于5-Fu对照组.     

双重载药多层海藻酸盐-壳聚糖缓释微球的制备及体外释放

采用滴注法将海藻酸钠与钙离子交联,制成负载血管内皮生长因子(VEGF)的藻酸钙核心球,利用层层自组装技术在核心球的表面依次包覆壳聚糖、海藻酸和壳聚糖,壳聚糖中负载万古霉素(VAN),形成多药载药缓控体系.采用正交实验考察海藻酸钠浓度、钙离子浓度及壳聚糖浓度对VEGF和VAN的药物包封率和载药量的影响,优化了制备工艺.采用扫描电子显微镜观察多层微球的表面、截面形貌及粒径,采用傅里叶变换红外光谱检测海藻酸盐与壳聚糖的自组装情况,分别采用酶联免疫吸附(ELISA)双抗体夹心法和紫外分光光度法检测VEGF和VAN的包封率、载药量及体外释放情况.结果表明,海藻酸钠最优浓度为0.04g/mL,氯化钙最优浓度为0.15g/mL,壳聚糖最优浓度为0.01g/mL.微球光滑圆整,均质实心,直径900~1100μm,VEGF的包封率达61.31%,VAN的包封率为3.48%.体外释放实验结果表明,VEGF缓释时间为15.5d,并出现2个释放高峰;VAN缓释时间为4.5d,释药情况平稳持续,无明显突释.双重载药多层包覆微球兼具控制感染和促进血管生成两种潜能,有望应用于组织工程骨的基础研究和临床实践.     

淫羊藿苷壳聚糖/明胶微球的制备及其体外释放研究

本试验以壳聚糖、明胶为载药基质,以中药淫羊藿苷为模拟药物,通过乳化交联的方法制备淫羊藿苷/壳聚糖/明胶微球。考察微球的理化特性,建立持续流动释放系统,检测了微球的体外释放特性和影响因素。微球的理化特性受工艺条件如搅拌速度、乳化剂用量、交联剂用量等因素影响。微球的体外释放速率与微球的粒径、交联度负相关,与载药量正相关。试验结果表明,壳聚糖、明胶可作为缓释微球的载体基质,微球制备工艺简单稳定,微球的释放速率可控,淫羊藿苷/壳聚糖/明胶微球是一种良好的药物释放体系。     

基于壳聚糖衍生物的蛋白质药物载体材料的制备及性能

在离子液体均相体系中合成了一种新型两亲性窄分子量分布的低聚壳聚糖衍生物月桂基-琥珀酰化壳聚糖(LSCOS). 以LSCOS为载体材料, 以牛血清蛋白(BSA)为模板蛋白, 以戊二醛为交联剂, 用油包水(W/O)乳化交联法制备了包载BSA的BSA/LSCOS缓释载药微球. 通过扫描电子显微镜(SEM)、 透射电子显微镜(TEM)及紫外-可见光谱(UV-Vis)研究了BSA/LSCOS比率和戊二醛/LSCOS比率对微球的形貌结构、 包埋率、 载药率和体外药物释放特性的影响. 结果表明, 在离子液体中合成的LSCOS包覆了BSA, 形成的微球粒径约为1 μm, 微球表面随BSA用量的增加变得光滑, 随戊二醛用量的增加变得粗糙. BSA的累积释放率与BSA包载量成正比, 与交联剂添加量成反比, 因此, 可通过控制蛋白质药物的添加比率和交联剂用量来控制蛋白质药物体外释放率.     

载药蛋白质/聚苯硼酸复合纳米微球制备及其释药性能研究

蛋白质纳米颗粒具有良好的生物相容性和生物降解性,易于进行额外的表面修饰,用作药物输送系统提高了生物利用度,减少了药物分子的毒副作用.本工作在利用苯硼酸基团与再生桑蚕丝蛋白(RSF)上相关侧基之间具有路易斯酸-碱配对反应的基础上,通过3-丙烯酰胺苯硼酸(APBA)在RSF水溶液中原位聚合,使RSF分子链重排形成微球并在表面负载抗炎中药,制备了载药丝蛋白/聚苯硼酸纳米微球.此尺寸分布均匀的微球直径约为550～600nm,表面光滑且在水中的分散性能良好;对乔松素、杜鹃素和地奥司明三种药物的负载率分别为7.8%,11.9%和13.4%,包封率分别为75.0%,89.1%和93.7%.载药微球控制释放约7d,且缓释行为具有pH响应性.丝蛋白/聚苯硼酸纳米微球与主体药物协同作用提高了自由基清除速度和清除效率,优于直接给药组.与此同时,将RSF改换为牛血清白蛋白或明胶蛋白,采用此方法也能制成尺寸分别为260和100nm的白蛋白/聚苯硼酸微球或明胶蛋白/聚苯硼酸微球.由此,三种不同尺寸、电性和药物释放速率的蛋白质/聚苯硼酸纳米微球有望适应多种静脉注射和皮下或腹腔注射药物传输的需求.     

微乳液法制备可共载水溶和脂溶药物的壳聚糖季铵盐乙醇脂质体的载药性能表征

采用微乳液法制备了可包载脂溶性和水溶性药物的羧甲基壳聚糖十八烷基季铵盐(OQCMC)乙醇脂质体,研究了OQCMC乙醇高分子脂质体的相图、粒径和电位、对药物的包封及释放能力及共载水溶性和脂溶性荧光染料后的细胞内递送能力.结果表明:OQCMC上长链季铵盐分子的取代度和共乳化剂乙醇的加入量对相图中微乳区域的面积影响不大;微乳液法可制备包载水溶性长春新碱(VCR)、脂溶性消炎痛(IMC)或二者共载的OQCMC载药微球,微球粒径为(52.40±0.55)nm,分布均匀;微乳液体系对VCR的最大载药率为22.7%,对IMC的最大载药率为20.1%,二者共载时,VCR的最大载药率为12.2%,IMC的最大载药率为10.0%;载药微球对药物具有缓控释功能.OQCMC乙醇高聚物脂质体可有效地包载荧光染料异硫氰酸荧光素FITC(水溶性)和尼罗红(脂溶性),并将二者递送到卵巢癌HO8901细胞内.     

壳聚糖多孔微球负载PdCl2选择性催化氢化氯代硝基苯的研究

以壳聚糖为原料，液体石蜡为分散介质，甲醛，戊二醛为交联剂，通过反相悬浮交联制备了粒径小于100μm的壳聚糖多孔微球；对制备壳聚糖多孔微球的影响因素进行了探讨，并用FTIR和SEM表征了多孔微球；XPS表明，壳聚糖多孔微球经PdCl2负载后，PdCl2与壳聚糖形成配合物，配位键是在PdCl2的Pd与壳聚糖的N之间形成。在常温常压下，PdCl2/壳聚糖多孔微球能选择性地催化还原氯代硝基苯为氯苯胺；对影响催化加氢的因素如反应温度、溶剂、催化剂用量和底物浓度作了探讨。     

阿司匹林-蒙脱土-壳聚糖缓释微球的制备及其体外释放性能

利用溶液法预先制备壳聚糖(Cs)-蒙脱土(MMT)复合材料(Cs-MMT),以Cs-MMT、Cs为原料,采用反相悬浮聚合法制得一种新型药物缓释体系阿司匹林-蒙脱土-壳聚糖载药微球(Asp-MMT-Cs)。采用FT-IR、SEM表征了Cs-MMT和Asp-MMT-Cs载药微球的结构及形态;设计正交实验优化了Asp-MMT-Cs载药微球的制备工艺;通过体外释放实验探讨了载药微球在不同模拟释放液中的释药规律。结果表明:所得微球球形度好,粒径分布较均匀;最优工艺制得的载药微球平均粒径为81.20μm,载药量为9.61%,包封率为76.78%。该缓释体系具有pH敏感性,更倾向于在pH较高的磷酸盐缓冲溶液中释放。     

Surface fabrication of hollow microspheres from N-methylated chitosan cross-linked with glutaraldehyde

We have successfully prepared biocompatible and biodegradable hollow microspheres with sizes between 2 and 5 mum using cyclohexane droplets as a template and the N-methylated chitosan (NMC) cross-linked with glutaraldehyde (GA) as the shell. The structure, morphology, and formation process of the hollow microspheres were characterized by FT-IR, (1)H and (13)C NMR, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). The results revealed that the microspheres exhibited a very smooth and hollow structure. This work confirmed that the hollow microspheres were accomplished by fabricating on the basis of chemical cross-linking on the surface of the emulsion droplets and by removing cyclohexane as core. The results from SEM and TEM indicated that the emulsion droplets covered with cross-linked NMC in the oil-in-water system aggregated together to form a precipitate of microspheres by coagulating with acetone. Moreover, the cross-linked NMC on the surface of the microspheres continuously cured to form the tight shell, whereas the inner area became a cavity with increase of the aging time, leading to the hollow microspheres. In addition, an anti-infective drug, ofloxacin (Floxin), encapsulated in the microspheres more rapidly released to reach 90 wt % at pH 7.4 within 8 h than at pH 1.2.     

离子凝胶反应法制备壳聚糖/N,O-羧甲基壳聚糖微球

以一氯乙酸与壳聚糖反应形成N,O-羧甲基壳聚糖两性聚电解质,分光光度法测定其等电点IEP=2．86。以此两性聚电解质与壳聚糖可以在一定条件下形成微球,光学显微镜和电子显微镜测试表明,控制两种聚电解质配比可以制备不同粒径大小的微球,而超声功率对微球粒径的影响较小。红外光谱测试表明微球中N,O-羧甲基壳聚糖羧基以羧酸根形式存在,分光光度与电导法联合测定表明两种聚电解质以离子凝胶作用形成微球,其最佳制备条件为IEP（CM-CHITOSAN）〈pH〈pKa（CS）,在此较宽的pH值范围内微球可稳定存在。     

Colon specific chitosan microspheres for chronotherapy of chronic stable angina

In the present work, chitosan microspheres with a mean diameter between 6.32 μm and 9.44 μm, were produced by emulsion cross-linking of chitosan, and tested for chronotherapy of chronic stable angina. Aiming at developing a suitable colon specific strategy, diltiazem hydrochloride (DTZ) was encapsulated in the microspheres, following Eudragit S-100 coating by solvent evaporation technique, exploiting the advantages of microbiological properties of chitosan and pH dependent solubility of Eudragit S-100. Different microsphere formulations were prepared varying the ratio DTZ:chitosan (1:2 to 1:10), stirring speed (1000-2000 rpm), and the concentration of emulsifier Span 80 (0.5-1.5% (w/v)). The effect of these variables on the particle size and encapsulation parameters (production yield (PY), loading capacity (LC), encapsulation efficiency (EE)) was evaluated to develop an optimized formulation. In vitro release study of non-coated chitosan microspheres in simulated gastrointestinal (GI) fluid exhibited a burst release pattern in the first hour, whereas Eudragit S-100 coating allowed producing systems of controlled release diffusion fitting to the Higuchi model, and thus suitable for colon-specific drug delivery. DSC analysis indicated that DTZ was dispersed within the microspheres matrix. Scanning electron microscopy revealed that the microspheres were spherical and had a smooth surface. Chitosan biodegradability was proven by the enhanced release rate of DTZ in presence of rat caecal contents.     

Chromatographic studies of mitomycin C degradation in albumin microspheres

Serum albumins and polylactic acid (PLA) have been used as bioerodable polymers in the preparation of drug-containing microspheres for parenteral drug delivery. The albumin microsphere may be prepared via either chemical cross-linking or heat denaturation of the protein. Heat-denatured albumin microspheres containing mitomycin C (MMC) have been used in pre-clinical and clinical investigations. Due to the high reactivity of MMC as a bifunctional alkylating agent, a study on the stability of MMC in the albumin and PLA microspheres has been carried out using a high-performance liquid chromatographic (HPLC) method. Human serum albumin (HSA) microspheres were prepared using an emulsion method via either heat denaturation at 120 or 170 degrees C or the use of 0.5 M biacetyl as a cross-linking agent. The PLA microspheres were prepared by an emulsion method at 55 degrees C. HPLC analysis of the HSA microspheres showed that about 37% of MMC was converted to 2,7-diaminomitosene derivatives in microspheres prepared by heat denaturation at 120 degrees C. The degradation increased to 82% when the microspheres were prepared with a denaturation temperature of 170 degrees C. The use of biacetyl as a cross-linking agent in the preparation of HSA microspheres resulted in a complete degradation of the incorporated MMC. Biacetyl was found to interact with MMC leading to the formation of 7-aminomitosene derivatives. In contrast to the albumin system, MMC may be incorporated into PLA microspheres without degradation.     

磁性壳聚糖微球的制备及对Cr(Ⅵ)的吸附性能研究

用壳聚糖包埋磁流体,用戊二醛交联制成磁性壳聚糖微球,并用红外光谱表征其结构。用制备的磁性壳聚糖微球吸附Cr(Ⅵ)离子,考察了其对Cr(Ⅵ)离子的吸附性能;探讨了吸附时间、溶液pH值、吸附剂用量、温度、Cr(Ⅵ)起始浓度以及其他离子存在对Cr(Ⅵ)离子去除率的影响。实验结果表明,磁性壳聚糖微球吸附Cr(Ⅵ)离子的最佳条件为:吸附平衡时间40 min,最佳吸附pH值6左右,磁性壳聚糖微球用量10 mg,温度升高有利于提高磁性壳聚糖微球的吸附效率,Cr(Ⅵ)离子起始质量浓度为12μg/mL,无机盐的存在引起磁性壳聚糖微球的吸附性能降低。并且考察了吸附剂的再生性能,实验结果表明磁性壳聚糖微球具有良好的重复使用性。     

Preparation and Characterization of Vanillin Cross-Linked Chitosan Microspheres of Pterostilbene

A vanillin cross-linked chitosan microsphere delivery system was established for stabilization and controlled release of pterostilbene. The prepared microspheres were characterized by SEM images, FT-IR spectra, thermogravimetry, and X-ray diffraction. FT-IR spectra results indicated that chitosan was cross-linked by vanillin successfully. Thermal analysis showed that pterostilbene had been totally incorporated into the microspheres and the encapsulation of pterostilbene decreases the rate of degradation and increases the stability. XRD analysis was conducted to confirm the results of DSC analysis. The release rate of pterostilbene from microspheres in pH 3.6 buffer solution could be up to 58.1 % within 48 h.     

Chitosan-Pectin Composite Gel Spheres: Effect of Some Formulation Variables on Drug Release

Chitosan-pectin composite gel spheres were prepared by ionotropic gelation method. Pectin solution containing indomethacin, a model drug, was extruded into a mixture of chitosan and calcium chloride. The release behavior of indomethacin from composite gel spheres was investigated in-vitro. The influence of factors affecting release behavior, such as type of pectin, molecular weight of chitosan, cross-linking time and release medium, were discussed in this study. Adding chitosan into gelation medium could retard the release of indomethacin from gel spheres. The different type of pectin used demonstrated slightly different drug release profiles. The higher molecular weight of chitosan showed less indomethacin release than the lower one. The increased cross-linking time slowed the drug release from composite gel spheres. The release of indomethacin from composite gel spheres was also dependent on the release medium. The drug release was slower in tris buffer where no phosphate ions which can induce the precipitation of calcium phosphate. The results suggested that the composite gel spheres of pectin and chitosan could be used as a controlled release drug delivery carrier.     

多孔磁性明胶微球的制备与结构表征

首先通过乳化法得到磁性明胶微球, 然后在高速搅拌条件下向乳液中直接加入正硅酸乙酯(TEOS), 制备出多孔磁性明胶微球. 用SEM, TEM观察了微球的微观形貌, 发现微球呈疏松多孔状结构. 用FT-IR, TGA, VSM等测试手段对微球的结构和性能进行表征. 结果表明, 二氧化硅掺杂于磁性明胶微球中. TEOS在反应中作为明胶微球的交联固化剂, 推测其固化机理是物理交联固化. 实验证实二氧化硅改性后, 磁性明胶微球内部磁性颗粒氧化速度有所降低. 所得到的多孔磁性明胶微球表现出铁磁性.     

Preparation of uniform-sized pH-sensitive quaternized chitosan microsphere by combining membrane emulsification technique and thermal-gelation method

In this study, uniform-sized pH-sensitive quaternized chitosan microsphere was prepared by combining Shirasu porous glass (SPG) membrane emulsification technique and a novel thermal-gelation method. In this preparation process, the mixture of quaternized chitosan solution and alpha-beta-glycerophosphate (alpha-beta-GP) was used as water phase and dispersed in oil phase to form uniform W/O emulsion by SPG membrane emulsification technique. The droplets solidified into microspheres at 37 degrees C by thermal-gelation method. The whole process was simple and mild. The influence of process conditions on the property of prepared microspheres was investigated and the optimized preparation condition was obtained. As a result, the coefficient of variation (C.V.) of obtained microspheres diameters was below 15%. The obtained microsphere had porous structure and showed apparent pH-sensitivity. It dissolved rapidly in acid solution (pH 5) and kept stable in neutral solution (pH 7.4). The pH-sensitivity of microspheres also affected its drug release behavior. Bovine serum albumin (BSA) as a model drug was encapsulated in microspheres, and it was released rapidly in acid solution and slowly in neutral medium. The novel quaternized chitosan microspheres with pH-sensitivity can be used as drug delivery system in the biomedical field, such as tumor-targeted drug carrier.